Search results for "ECHO-7"

showing 6 items of 6 documents

Erratum: Melanoma Unknown Primary Brain Metastasis Treatment With ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease. Melanoma brain metastases have many severe side effects and, unfortunately, any disease related to the brain has limited therapeutic options due to the blood–brain barrier. The course of the disease after a treatment course is complicated to predict, and it is difficult to obtain long-lasting remission. In this report, we describe a female patient with unknown primary melanoma brain metasta…

Cancer ResearchCase ReportBlood–brain barrierblood–brain barrierlcsh:RC254-282Text miningmelanoma brain metastasisRigvir®medicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalEcho (computing)medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virusmedicine.anatomical_structureOncologymelanoma unknown primaryCancer researchUnknown primaryErratumbusinessBrain metastasisFrontiers in Oncology
researchProduct

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

2020

Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not rece…

Metastatic melanomaRigvirCase ReportVirus03 medical and health sciences0302 clinical medicinemelanomamedicineVirotherapyoncolytic virus030304 developmental biologylcsh:R5-9200303 health sciencesbusiness.industryMelanomaGeneral MedicineStage iiibmedicine.diseaseOncolytic virus030220 oncology & carcinogenesisCancer researchvirotherapySkin cancerlcsh:Medicine (General)businessECHO-7metastatic melanomaSAGE Open Medical Case Reports
researchProduct

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A c…

2020

Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

Oncologymedicine.medical_specialtyRigvirmedicine.medical_treatmentlcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAdjuvant therapymelanomaMedicineRadical surgeryStage (cooking)ECHO-7 virusoncolytic viruslcsh:R5-920business.industryMelanomalcsh:RGeneral Medicinemedicine.diseaseOncolytic virusTolerability030220 oncology & carcinogenesisoncologyECHO‐7 virusbusinesslcsh:Medicine (General)AdjuvantRare diseaseuterine cervixClinical Case Reports
researchProduct

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro

2018

Background: The role of oncolytic viruses in cancer treatment is increasingly studied. The first oncolytic virus (Rigvir®, ECHO-7) was registered in Latvia over a decade ago. In a recent retrospective study Rigvir® decreased mortality 4.39-6.57-fold in stage IB-IIC melanoma patients. The aims of the present study are to test the effect of Rigvir® on cell line viability in vitro and to visualize the cellular presence of Rigvir® by immunocytochemistry. Methods: The cytolytic effect of Rigvir® on the viability of FM-9, RD, AGS, A549, HDFa, HPAF‑II, MSC, MCF7, HaCaT, and Sk-Mel-28 cell lines was measured using live cell imaging. PBMC viability was measured using flow cytometry. The presence of …

0301 basic medicinemedicine.diagnostic_testMelanomaBiologymedicine.diseasePeripheral blood mononuclear cellOncolytic virusFlow cytometry03 medical and health sciencesHaCaTCytolysis030104 developmental biologyimmunocytochemistryOncologyCell cultureRigvir.Cancer researchmedicineViability assayECHO-7 viruscell viabilityResearch Paperoncolytic virusJournal of Cancer
researchProduct

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency for forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of this disease. Melanoma brain metastases have many severe side effects and unfortunately, any disease related to the brain has limited therapeutic options due to the blood brain barrier. The course of the disease after completing a treatment course, and stopping the treatment, is complicated to predict and is difficult to obtain long-lasting remission. In this report we describe a female patient with un…

0301 basic medicineOncologyNasal cavityCancer Researchmedicine.medical_specialtyCentral nervous systemDiseaseMalignancyblood–brain barrierlcsh:RC254-282Metastasis03 medical and health sciences0302 clinical medicinemelanoma brain metastasisInternal medicinemedicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologymelanoma unknown primary030220 oncology & carcinogenesisbusinessBrain metastasisFrontiers in Oncology
researchProduct

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report: Erratum.

2019

Abstract Rationale: Of all the parts of the larynx, the glottis has the highest frequency of cancer. With disease progression, the vocal cord movement is affected and for advanced stages its anatomical and functional preservation is rarely achievable, if at all. Patient concerns: Here we describe a 72-year-old patient who presented with hoarseness for a year and was only able to whisper. Diagnosis: A computed tomography (CT) scan of the vocal cords (without contrast) showed higher density tissue. Histological examination disclosed a well-differentiated verrucous squamous cell carcinoma of the glottis. Interventions: The patient was treated with the oncolytic ECHO-7 virus Rigvir without any …

5700Rigvirlaryngeal cancerglottisClinical Case ReportECHO-7 virusResearch Articleoncolytic virusMedicine
researchProduct